Stocks
Intra-Cellular Therapies (ITCI) Debt/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | 1.30 | 2.72 | 1.35 | 2.17 | 3.03 | 3.50 | |||
| Changes by years, y/y, % | -39% | +108% | -50% | +60% | +40% | +7.2% | |||
Intra-Cellular Therapies. Debt/EBITDA
Intra-Cellular Therapies. Debt/EBITDA, changes, %
Intra-Cellular Therapies (ITCI) Debt/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| Debt/EBITDA | 2.17 | 2.49 | 2.76 | 3.02 | 3.50 | 3.50 | ||
| Changes by years, y/y, % | -12% | +24% | +38% | +39% | +61% | |||
| Changes by quarters, q/q, % | +0% | +15% | +11% | +10% | +16% | |||
